DEVELOPING · Attributed source report · science · World

Trial results posted: A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NULLPEN · Source published 11/10/2026, 12:00:00 AM UTC

ClinicalTrials.gov records the first posting of results for study NCT07226752 on 2026-11-10. A registry posting does not establish that a treatment is effective or safe.

Why it matters

New trial results are available for scrutiny. This report describes the posting only; it does not evaluate the findings.

What remains uncertain

The study findings have not been independently assessed by NULLPEN.

The source record

National Library of Medicine, National Institutes of Health

Source: ClinicalTrials.gov, National Library of Medicine, United States. Registry entries are filed by trial sponsors; the registry does not verify them.Retrieved 2026-11-10T18:50:23.679Z. Updated on NULLPEN 2026-11-10T18:50:25.285Z.Revision sha256:26f15e27cb1ce71a82af83bfa89effe87fcde36e87662d31431083858b65db93